Erythropoiesis stimulating agents, blood transfusion, and the practice of medicine

American Journal of Hematology

Volumn 85, Issue 11, 2010, Pages 835-837

  Goodnough, Lawrence Tim ^a   Shander, Aryeh S ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; DRUG INDUCED DISEASE; DRUG UTILIZATION; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MEDICAID; MEDICAL PRACTICE; MEDICARE; NOTE; PRIORITY JOURNAL; REIMBURSEMENT;

ANEMIA; BLOOD TRANSFUSION; HEMATINICS; HUMANS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 77958615383     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21870     Document Type: Note

References (30)

1. Centers for Medicare and Medicaid Services. Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for non-renal disease indications (CAG-00383N). Issue date: July 30, 2007. Last modified: January 14, 2010. Available at: (Accessed on August 20, 2010).
2. Hess G, Nordyke RJ, Hill J, et al. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Amer J Hematol, in press.
3. NCI Cancer Bulletin. (Accessed August 20, 2010).
4. FDA press release: FDA receives new data on risks of anemia drugs consistent with previous data on tumor growth and death. (Accessed August 20, 2010).
5. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-460.
6. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
7. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027-1032.
8. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
9. Overgaard J, Hoff C, Sand Hansen H, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of head and neck (HNCSS): The Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]. Eur J Cancer Suppl 2007; 5: 7.
10. Smith REJr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1040-1050.
11. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008; 108: 317-325.
12. Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis-stimulating agents-Time for a reevaluation. N Engl J Med 2010; 362: 189-192.
13. Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 2006; 28: 801-831.
14. U.S. Department of Health & Human Services. The 2007 National Blood Collection and Utilization Survey Report. 2010.
15. Larholt K, Burton TM, Hoaglin DC, et al. Clinical and patient-reported outcomes based on achieved hemoglobin levels in chemotherapy-treated cancer patients receiving erythropoiesis-stimulating agents. Commun Oncol 2009; 6: 403-408.
16. Vansteen Kiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled randomized phase III trial of darbopoietin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-1220.
17. Henry DH, Brooks BJJr, Case DCJr, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995; 1: 252-260.
18. Hershman DL, Buono DL, Malin J, et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009; 101: 1633-1641.
19. Murphy M, Wallington T, Kelsey P, et al., British Committee for Standards in Hematology. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001; 113: 24-31.
20. Simon TL, Alverson DC, AuBuchon J, et al. Practice parameter for the use of red blood cell transfusions: Developed by the red blood cell administration practice guideline development Task Force of the College of American Pathologists. Arch Pathol Lab Med 1998; 122: 130-138.
21. Hess G, Hill J, Clough J, et al. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels. Curr Med Res Opin 2008; 24: 815-819.
22. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts-Blood transfusion. N Engl J Med 1999; 340: 438-447.
23. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504.
24. Epstein JS, Holmberg JA. Progress in monitoring blood safety. Transfusion 2010; 50: 1408-1412.
25. U.S. Circular for Information for the Use of Human Blood and Blood Components. AABB, the American Red Cross, America's Blood Centers, and the Armed Services Blood Program. August 2009. Available at: (Accessed on August 20, 2010).
26. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007; 44: 32-41.
27. FDA Safety Announcement: Information on erythropoiesis-stimulating agents (ESA) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). February 16, 2010. Available at: (Accessed on August 2010).
28. Littlewood TJ, Bajetta E, Nortier JW, et al.; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
29. Adamson JH. Erythropoietic-stimulating agents: The cancer progression controversy and collateral damage to the blood supply. Transfusion 2009; 49: 824-826.
30. Vekeman F, Bookhart BK, White J, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009; 49: 895-902.